Tests a non-surgical approach for breast cancer after chemotherapy
Tests whether breast cancer patients who respond well to chemotherapy can avoid surgery.
Key facts
- Who runs it
- Ohio State University Comprehensive Cancer Center
- Where
- Columbus, United StatesSee the site
- Trial code
- Registry title
- Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 84 people, planned
- Starts
- 15 Jan 2027
- Expected to end
- 31 Jan 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Neoadjuvant Chemotherapy
- Radiation Therapy
- MRI
- Breast Cancer Surgery
- Biopsy
- Biospecimen collection
- Record updated
- 9 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with early-stage breast cancer of the HER2-positive or triple negative type who plan to have chemotherapy before surgery and radiation. It tests whether some people can avoid surgery.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Early-stage breast cancer (cT1-3 N0 or cT1-2 N1) that is HER2-positive or triple negative
- Earlier treatment
- Planning to receive chemotherapy before surgery (neoadjuvant chemotherapy) and radiation therapy
- Biomarker or test result
- HER2-positive or triple negative tumor type
Main reasons for not taking part
- Pregnant or breastfeeding
- Extensive calcifications in the breast (complex cases are discussed by the study doctors)
- Skin involvement or distant metastases
- Inmate or prisoner
- Treatment with an investigational drug or other intervention during breast cancer treatment
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 18 years or older
- Early-stage breast cancer diagnosis (cT1-3 N0 or cT1-2 N1) and a Human Epidermal Receptor 2 (HER2)-positive or triple negative breast cancer (TNBC) tumor molecular subtype
- Cannot have extensive calcifications in the breast (for complex cases, a patient with calcification's eligibility will be discussed by the study co-principal investigators (PIs) and the treating physicians)
- Planning to receive neoadjuvant chemotherapy (NAC) and radiation therapy (RT)
Who cannot take part
- Treatment with an investigational drug or other intervention throughout their breast cancer treatment
- Pregnancy or lactation
- Inmate or prisoner
- Patients with skin involvement and/or distant metastases
Where in United States
- Ohio State University Comprehensive Cancer CenterColumbus, United StatesContact: Sachin Jhawar, MDNot yet recruiting
About the trial
What the trial wants to find out
This study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer.
The 2 groups in the trial
- Arm A (eeCR, non-surgical)Treatment being tested
Patients will receive standard of care (SOC) neoadjuvant chemotherapy and will be evaluated for enhanced clinical complete response (ecCR) after treatment. Participants who achieve an ecCR will be placed in the non-surgical arm. Participants will receive radiation therapy and routine and additional screening MRIs during follow up.
Treatment: Neoadjuvant Chemotherapy, Radiation Therapy, MRI, Biopsy, and Biospecimen collection
- Arm B (non-eeCR, surgical)Treatment being tested
Patients will receive standard of care (SOC) neoadjuvant chemotherapy and will be evaluated for enhanced clinical complete response (ecCR) after treatment. Participants who do not achieve an ecCR will be placed in the surgical arm. Participants will undergo a lumpectomy or mastectomy, receive radiation therapy, and routine follow-up.
Treatment: Neoadjuvant Chemotherapy, Radiation Therapy, MRI, Breast Cancer Surgery, Biopsy, and Biospecimen collection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
- Plain-language title
- Tests a non-surgical approach for breast cancer after chemotherapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 November 2026